FORGOT YOUR DETAILS?

LINK Healthcare receives marketing approval for EQUISIN® in South Africa

by / Tuesday, 26 August 2014 / Published in News

LINK Healthcare receives marketing approval for EQUISIN® in South Africa

 EQUISIN®, (exemestane) aromatase inhibitor is used in the treatment of breast cancer

 Link’s brand is first-to-market generic to receive approval in South Africa

 Link’s range of specialist oncology medicines is set to increase in the coming months

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 26th August 2014

 

Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has launched its first generic oncology product exemestane (marketed as EQUISIN) in South Africa. Exemestane is a member of the class of drugs known as aromatase inhibitors which block the synthesis of oestrogen thereby slowing the growth of susceptible cancers. 1 in 35 women in South Africa will be diagnosed with breast cancer making it the most common cancer affecting South African women.

Mr John Bacon, Chairman of LINK Healthcare said: “We are excited to launch the first-to-market generic exemestane. LINK anticipates further approvals of both innovative and generic oncology products in the coming months to bolster our South African portfolio.

About EQUISIN

EQUISIN is indicated for:

Treatment of advanced oestrogen receptor positive breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Adjunctive treatment of postmenopausal women with oestrogen receptor-positive
 

About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.
In Australia and Southern Africa the group also commercialize a unique range of medical technology products focused in the specialist areas of advanced wound care, diabetes and point of care testing.

For more information about LINK Healthcare visit www.linkhealthcare.com.au

FOR FURTHER INFORMATION
Contact LINK Healthcare on 61 (2) 8401 9777
Corporate and Media Enquiries:
Mr John Bacon
Executive Chairman

 

TOP